Debevoise Advises Allergan on $2.9 Billion Acquisition of LifeCell Corporation

20 December 2016

Debevoise & Plimpton LLP is advising Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, in its acquisition of LifeCell Corporation from Acelity, a global advanced wound care and regenerative medicine company. The cash transaction is valued at approximately $2.9 billion, subject to customary adjustments.

The acquisition combines LifeCell's regenerative medicines business, including its high-quality and durable portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders. Allergan currently anticipates closing the transaction in the first half of 2017.

The Debevoise team is led by partner Andrew L. Bab and includes partners Jennifer L. Chu, Jeffrey P. Cunard, Gary M. Friedman and Jonathan F. Lewis and associates Matthew M. Delja, Samuel M. Duncan, Michelle M. Hillenbrand, Douglas M. Hirn, Andrew G. Jamieson, Sue Meng and Nicholas C.H. Roper.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. We deliver effective solutions to our clients’ most important legal challenges, applying clear commercial judgment and a distinctively collaborative approach.